All authors contributed equally to this article.
Progress in immune-based therapies for type 1 diabetes
Article first published online: 10 APR 2013
© 2013 British Society for Immunology
Clinical & Experimental Immunology
Special Issue: Review series on Adoptive Cell Therapy. Immunology in the clinic: diabetes therapies and biomarkers
Volume 172, Issue 2, pages 186–202, May 2013
How to Cite
von Herrath, M., Peakman, M. and Roep, B. (2013), Progress in immune-based therapies for type 1 diabetes. Clinical & Experimental Immunology, 172: 186–202. doi: 10.1111/cei.12085
- Issue published online: 10 APR 2013
- Article first published online: 10 APR 2013
- Accepted manuscript online: 5 FEB 2013 08:06AM EST
- Manuscript Accepted: 30 JAN 2013
Immune-based therapies that prevent type 1 diabetes or preserve metabolic function remaining at diagnosis have become a major objective for funding agencies and international trial consortia, and receive backing from notable patient advocate groups. The development of immune-based therapeutic strategies in this arena requires a careful balancing of the risks of the therapy against the potential benefits, because many individuals are diagnosed or identified as being at increased risk of disease in early childhood, a period when manipulation of the developing immune system should be undertaken with caution. In addition, a therapy exists (daily insulin injection) that is life-saving in the acute stages of disease and can be used effectively over a lifetime as maintenance. Conversely, the disease is increasing in incidence; is peaking in ever-younger age groups; carries significant risk of increased morbidity and early mortality; and remains difficult to manage effectively in many settings. With these issues in mind, in this article we review progress towards immune-based strategies for this chronic autoimmune disease.